Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway

Fig. 4

AKR1C1 promotes cisplatin-resistance enzymatic-independent manner. a Cisplatin dose-response curve in wild type AKR1C1, AKR1C2, and domain-negative AKR1C1-E127D Cal-27 cells. b to d. b The cisplatin regimen (upper) and in vivo tumor burden (bottom, n = 5). The cisplatin was given 2 mg /kg through intraperitoneal injection (i.p.). c and d. The tumor image and tumor weights (d) from (c) and the scale bar indicates 1 cm length

Back to article page